Advertisement
Advertisement
GDTC
CytoMed Therapeutics Limited Ordinary Shares
0.80
USDSponsored
-0.02
-2.58%
Aug 10, 16:00 UTC -4
Closed
After-Market
0.84
+0.04
+5.49%
GDTC Earnings Reports
Positive Surprise Ratio
No Data Available for GDTC
0%
Next Report
Date of Next Report
Sep 28, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/--
CytoMed Therapeutics Limited Ordinary Shares earnings per share and revenue
On May 04, 2026, GDTC reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -0.04 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 132.60 thousand, with a --% difference.
Looking ahead to Q2 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were CytoMed Therapeutics Limited Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, CytoMed Therapeutics Limited Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to CytoMed Therapeutics Limited Ordinary Shares's Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is CytoMed Therapeutics Limited Ordinary Shares expected to report next?
The next earning report is scheduled for Sep 28, 2026.
What are the forecasts for CytoMed Therapeutics Limited Ordinary Shares's next earnings report?
Based on --
analysts, CytoMed Therapeutics Limited Ordinary Shares is expected to report EPS of -- and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement